TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
The global Hemophilia Drugs market was valued at US$ 13100 million in 2022 and is projected to reach US$ 17160 million by 2029, at a CAGR of 3.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ?Emicizumab? by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ?Eloctate? for type A and ?Aprolix? for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
This report aims to provide a comprehensive presentation of the global market for Hemophilia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Drugs. This report contains market size and forecasts of Hemophilia Drugs in global, including the following market information:
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market?s growth over the forecast period.
We surveyed the Hemophilia Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hemophilia Drugs Market Segment Percentages, by Type, 2022 (%)
Global Hemophilia Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hemophilia Drugs Market Segment Percentages, by Application, 2022 (%)
Global Hemophilia Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hemophilia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hemophilia Drugs revenues share in global market, 2022 (%)
Key companies Hemophilia Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Hemophilia Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Outline of Major Chapters:
